| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue, net | 14,544 | 13,459 | 10,698 | 15,425 |
| Cost of product revenue | 1,774 | 1,944 | 1,262 | 1,561 |
| Research and development | 52,358 | 51,081 | 42,857 | 37,054 |
| Selling and marketing | 13,088 | 13,729 | 14,148 | 10,573 |
| General and administrative | 16,022 | 14,346 | 16,348 | 12,235 |
| Total costs and operating expenses | 83,242 | 81,100 | 74,615 | 61,423 |
| Loss from operations | -68,698 | -67,641 | -63,917 | -45,998 |
| Interest income | 3,729 | 3,455 | 3,826 | 5,653 |
| Interest expense | 3,002 | 3,016 | 2,984 | 3,224 |
| Gain on disposal of items of property and equipment | - | 29 | - | - |
| Change in fair value of derivative liabilities | -1,447 | -641 | -978 | 7,076 |
| Total other income (expense), net | -720 | -173 | -136 | 9,505 |
| Net loss | -69,418 | -67,814 | -64,053 | -36,493 |
| Earnings per share, basic | -0.38 | -0.39 | -0.38 | -0.22 |
| Earnings per share, diluted | -0.38 | -0.39 | -0.38 | -0.22 |
| Weighted average number of shares outstanding, basic | 183,919,808 | 172,594,662 | 169,396,989 | 166,992,735 |
| Weighted average number of shares outstanding, diluted | 183,919,808 | 172,594,662 | 169,396,989 | 166,992,735 |
OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL)